Although genetic abnormalities associated with hematological malignancies are readily identified, the natural history of human leukemia cannot be observed because initiating and subsequent transforming events occur before clinical presentation. Furthermore, it has not been possible to study leukemogenesis in vitro as normal human cells do not spontaneously transform. Thus, the nature and sequence of genetic changes required to convert human hematopoietic cells into leukemia cells have never been directly examined. We have developed a system where the first step in the leukemogenic process is an engineered disruption of differentiation and self-renewal due to expression of the TLS-ERG oncogene, followed in some cases by overexpression of hTERT. In two of 13 experiments, transduced cells underwent step-wise transformation and immortalization through spontaneous acquisition of additional changes. The acquired karyotypic abnormalities and alterations including upregulation of Bmi-1 and telomerase all occur in acute myeloid leukemia (AML), establishing the relevance of this system. One resultant cell line studied in depth exhibits cellular properties characteristic of AML, notably a hierarchical organization initiated by leukemic stem cells that differentiate abnormally. These findings provide direct evidence for multiple cooperating events in human leukemogenesis, and provide a foundation for studying the genetic changes that occur during leukemic initiation and progression.
Introduction
The hematopoietic system is organized as a hierarchy maintained by rare hematopoietic stem cells (HSC) that self-renew and differentiate to produce mature blood lineages, ensuring a lifetime of blood production. When the regulatory signals governing these normal processes become deregulated, leukemias can result, characterized by an accumulation of immature blast cells that fail to differentiate into functional cells. Recent studies showing that leukemic stem cells (LSC) retain the ability to regulate self-renewal 1 suggest that the effects of transforming mutations are layered onto the normal developmental framework of hematopoietic cells, resulting in a leukemic clone that has an aberrant developmental hierarchy but still retains aspects of normal maturation.
Critical components of the cellular transcriptional apparatus required for normal differentiation have been identified on the basis of their disruption in more than 100 distinct chromosomal translocations associated with acute myeloid leukemia (AML). 2 Although aberrant maturation is a critical facet of leukemogenesis, full transformation of hematopoietic cells is thought to be a multistep process requiring the acquisition of additional events conferring self-renewal, proliferative, and anti-apoptotic advantages. 3 However, the nature and sequence of genetic changes required to generate a leukemic population are poorly understood. This is especially true in humans due to the lack of experimental systems that effectively model leukemogenesis. Progress has recently been made in defining the molecular events needed to convert normal human nonhematopoietic somatic cells into cancer cells. 4 Although the genetic events involved in converting normal hematopoietic cells into leukemic cells may be similar in principle to those elucidated for solid tumors, processes specific to hematopoietic cells will affect which particular pathways and/or components are perturbed in leukemogenesis.
Until recently, most of our understanding of the leukemogenic process and the genes involved was extrapolated from analysis of human leukemic cell lines and from mouse models. The latter have been used effectively to investigate the role of leukemogenic proteins, but due to species-specific differences in biology, do not always accurately recapitulate the process that occurs in humans. [5] [6] [7] Additionally, there are inherent differences in the mechanisms that govern the neoplastic process in human and mouse cells. [8] [9] [10] Human leukemic cell lines have also proven to be a useful tool for studying leukemogenesis, but harbor many pre-existing uncharacterized genetic alterations. Thus, it is not possible to assess the temporal contribution of individual changes to leukemic initiation and progression. Furthermore, expression of candidate oncogenes on the genetic background of cell lines may not have the same effects as expression in primary cells. 11, 12 Importantly, many cell lines do not recapitulate the hematopoietic developmental hierarchy, thus the full spectrum of effects induced by genetic changes cannot be assessed in all lineages. These observations underscore the need for experimental systems in which primary human hematopoietic cells are the targets for delivery of protooncogenes. In particular, evidence from xenotransplantation studies indicates that AML often originates within the normal stem cell compartment rather than in committed progenitors. 1, 13, 14 Thus, in order to accurately recapitulate the process occurring in vivo, experimental leukemogenesis models should effectively target the most primitive hematopoietic cells for transformation.
Recently, we and others have focused on the transduction of primary human cells with genes implicated in leukemogenesis. Transduction of primitive human cord blood (CB) cells with AML1-ETO, a fusion gene associated with the myelocytic subtype of AML, results in sustained growth of transduced cells for up to 8 months with maintenance of primitive CD34 þ cells and multilineage differentiation capacity. 15 HOXB4 transduction has also been shown to result in expansion of primitive hematopoietic progenitors, including in vivo repopulating cells, seemingly without any alteration in differentiation properties, 16 but long-term proliferation of HOXB4-expressing cells in vitro was not assessed. In these reports, the introduction of a single genetic change was insufficient to induce full transformation of hematopoietic cells, in keeping with what has been observed in murine studies. [17] [18] [19] However, direct demonstration of the multistep nature of human leukemogenesis is still lacking.
We have previously reported the effects of transducing normal lineage depleted (Lin À ) CB cells with TLS-ERG, a fusion gene associated with multiple subtypes of AML. 20, 21 TLS-ERG was able to initiate a preleukemic state, with an early block in erythroid differentiation and perturbation of myeloid differentiation, resulting in accumulation of immature myeloid cells. Myeloid progenitors exhibited increased self-renewal, 22 and cells could proliferate for 2 to 3 months in suspension culture (unpublished data). However, these studies used retroviral transduction techniques that do not efficiently target in vivo repopulating cells. 23 In the current study, we incorporate recent improvements in gene transfer protocols 24 to express TLS-ERG in more primitive human hematopoietic cells, allowing sustained proliferation for a longer period in culture. Disruption of the differentiation, proliferation, and self-renewal of primitive hematopoietic cells through introduction of TLS-ERG set up an environment that permitted the spontaneous occurrence of further genetic and epigenetic alterations. Using this approach, we have achieved full leukemic conversion of normal human hematopoietic cells, with recreation of the functional and phenotypic hierarchy of AML. The identified secondary molecular alterations acquired by the resultant transformed cell lines are associated with human AML. Our findings provide direct evidence for the occurrence of multiple cooperating events in human leukemogenesis.
Materials and methods

Sample collection and purification
Samples of CB were obtained according to procedures approved by the institutional review boards of University Health Network and Trillium Hospital. CB samples were collected, purified, and stored as described previously. 24 The efficiency of primitive CD34 þ cell enrichment was 30-78%.
TLS-ERG retroviral infection
PG13-MSCV-TLS-ERG or PG13-MSCV-Neo retroviral supernatant was harvested from packaging cell lines 22 and Lin À CB cells were infected 24 as previously described. Gene transfer efficiency was 6-26% for TLS-ERG and 12-43% for Neo.
hTERT lentiviral infection protocol hTERT 25 or GFP cDNA was cloned into a third-generation lentiviral vector backbone 26 containing an IRES-pac selection cassette. Viral supernatants pseudotyped with the vesicular stomatitis virus G protein were generated as previously described. 27 Infections were carried out at a multiplicity of infection of 40-100, using functional titers determined by infection of HeLa cells. Gene transfer efficiency into TLS-ERGtransformed cells ranged from 4 to 64% for hTERT and 19 to 100% for GFP.
Liquid culture and progenitor assays
Infected cells were cultured in IMDM supplemented with 15% FCS, 20 ng/ml SCF, and 2 ng/ml IL-3 (Amgen, Thousand Oaks, CA, USA), and containing 1500 mg/ml G418 (retroviral infected cells) or 250-400 ng/ml puromycin (lentiviral infected cells). Cells were harvested 1-2 times per week and reseeded at 4 Â 10 5 cells/ml. Population doublings (PD) were calculated following 6-8 days of selection in G418.
Colony-forming cells (CFC) were assayed by plating in methylcellulose cultures as previously described 28 and scored after 12-14 days.
For limiting dilution assays, cells were seeded into wells with conditioned media. Wells in which cells expanded by more than 5 PD over 5 weeks were scored as positive. Target cell frequency was calculated by Poisson statistics as previously described. 29 
Histochemistry and flow cytometry
Cytospin slides were prepared using 5 Â 10 4 cells. Cell morphology was assessed by May-Grü nwald-Giemsa staining. Staining for myeloperoxidase (MPO) and nonspecific esterase (NSE) was performed on fixed slides using standard methodology.
Flow cytometric analysis was performed using a FACSCalibur (Becton Dickinson, San Jose, CA, USA). Isotype controls were stained with mouse IgG conjugated to FITC, PE (Becton Dickinson), and PC5 (Coulter, Fullerton, CA, USA). Antibodies used to stain cells were FITC-conjugated anti-CD15, anti-CD61, PE-conjugated anti-CD11b, anti-CD14, anti-CD36, anti-CD56 (Becton Dickinson), and FITC-conjugated anti-CD7, anti-CD71, PE-conjugated anti-CD10, PC5-conjugated anti-CD33, anti-CD34 (Coulter). Human cell engraftment in transplanted mice was determined using human-specific anti-CD45-FITC (Becton Dickinson) or anti-CD45-PC5 (Coulter).
Transplantation into NOD/SCID mice
Eight-week-old NOD/LtSz-scid/scid (NOD/SCID) mice were bred and maintained in the defined flora animal facility at the Ontario Cancer Institute. Cells were transplanted by intravenous or intrafemoral (IF) injection into sublethally irradiated mice (360 cGy from a 137 Cs g-irradiator) according to our standard protocol. 28, 30, 31 Mice received alternate-day intraperitoneal injections of human cytokines (10 mg SCF, 6 mg IL-3, and 6 mg GM-CSF, Amgen) for the first 2 weeks.
Retroviral integration site analysis
DNA was digested with BamHI and Southern blot analysis performed using an N-terminal TLS fragment. To clone the integration site, linear amplification-mediated PCR was performed as previously described. 32 
Expression analysis
For quantification of mRNA levels of Bmi-1, FBP17, and GAPDH, qRT-PCR was carried out with SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol, using the ABI PRISM 7700 sequence detection system (Applied Biosystems). Expression data for Bmi-1 and FBP17 were corrected for the amount of input RNA by GAPDH expression. The following primer sets were used:
0 . Western blot analysis was carried out using standard methodology and visualized by chemiluminescence (Amersham, Sunnyvale, CA, USA). Mouse monoclonal antibodies against Bmi-1 (Abcam, Cambridge, MA, USA) and Actin (SigmaAldrich, Oakville, Ontario, Canada) were used with a goat antimouse HRP secondary (Santa Cruz, CA, USA) according to the manufacturer's protocols.
Cytogenetic analysis
Cells were incubated with 0.03 mg/ml colcemid for 4 h at 371C, treated with 0.075 M KCl for 30 min at 371C, and fixed in methanol-acetic acid. Dropped cells were Giemsa stained and analyzed according to standard methods. 33 Spectral karyotyping was carried out on freshly prepared slides using SKY Paints according to the manufacturer's instructions (ASI, Carlsbad, CA, USA). A total of 10 spectral images were acquired and analyzed with an SD 200 Spectral Bio-imaging System (ASI Ltd., Migdal Haemek, Israel) attached to a Zeiss microscope (Axioplan 2) using SKYVIEW (version 1.6) software (ASI).
Measurement of telomerase activity
Telomerase activity was measured using the telomeric repeat amplification protocol (TRAP) (Intergen, Purchase, NY, USA). 34 Protein titrations were performed to ensure that the TRAP was in the linear range of the assay. Telomerase extension products were analyzed using ImageQuant software (Amersham). Extract from HeLa cells was used as a positive control. 
Results
TLS-ERG expression in CB cells induces extended proliferation of myeloid progenitors and incomplete myeloid maturation
We have previously reported that TLS-ERG alters myeloid and erythroid differentiation of normal human hematopoietic progenitors. 22 Despite increased self-renewal of myeloid progenitors, bulk cultures of TLS-ERG-expressing cells (hereafter referred to as TLS-ERG cells) were only able to proliferate for up to 90 days in suspension cultures. We hypothesized that transduction of more immature cells with greater proliferation and self-renewal capacity might lead to a greater extension of replicative lifespan. CD34-enriched Lin À CB cells were infected with either MSCV-TLS-ERG or control MSCV-Neo retroviral vectors using protocols shown to transduce primitive cells more efficiently than our previous methods, 24 and transduced cells were cultured in myeloid promoting conditions. In all samples tested, TLS-ERG cells exceeded Neo controls in both total cellular output and duration of proliferation ( Figure 1a ). TLS-ERG cells proliferated for up to 217 days, reaching a maximum cumulative expansion of 31 population doublings (PD), compared to 41 days and seven PD for control cells. An increase in the number of CFC was observed for TLS-ERG cells, peaking at approximately 167 days (Figure 1b) . The parallel expansion of CFC and total cell number suggests that proliferation of TLS-ERG cells in culture is sustained by an expanding pool of progenitors, and that loss of these leads to eventual decline of the bulk culture.
TLS-ERG cells exhibited incomplete myeloid differentiation as assessed by cell surface phenotype. The majority of cells expressed the pan-myeloid marker CD33 (Figure 1c) . Expression of CD11b, a marker associated with myeloid differentiation, increased rapidly after infection and was maintained on most cells throughout the duration of culture. Granulocytic (CD15) and monocytic (CD14) lineage markers were expressed on a significant percentage of cells (Figure 1d ) (range 10-70 and 2-30%, respectively). In addition, cells expressing the primitive marker CD34 were observed in all cultures undergoing active proliferation (Figure 1e ( Figure 1f) . These results further support the concept that TLS-ERG expression leads to the enhanced growth and expansion of progenitor cells that give rise to more mature but aberrantly differentiating progeny throughout the duration of culture. However, TLS-ERG cells are not immortal and eventually stop proliferating, suggesting that although TLS-ERG can initiate a leukemogenic program, it is not sufficient to fully transform primary human cells.
Spontaneous immortalization of TLS-ERG cells after long-term culture
In one of 13 experiments, TLS-ERG cells exhibited atypical growth kinetics compared to other cultures (Figure 2a) . After 3 months in culture, the proliferation rate began to plateau, but subsequently accelerated (Figure 2b) , and remained at this higher level for over 27 months. These cells, which we have termed TEX, undergo one PD every 1.8 days, and have expanded beyond 284 PD. Thus, TEX cells appear to be immortalized. The phenotype of TEX cells is distinct from that of typical TLS-ERG cells. Whereas TEX cells are also CD33 þ (Figure 2c ), they do not express CD14 or CD15 (Figure 2d) , and CD11b expression is low or absent on most cells (Figure 2e ). Small numbers of TEX cells expressing CD36 and CD61, the primitive marker CD7, the erythroid-associated transferrin receptor CD71, and lymphoid markers CD56 and CD10 could be detected during culture (data not shown). Interestingly, the proportion of CD34 þ cells increased rapidly after 240 days of culture from 8 to 93% by 283 days, and has remained at over 90% (Figure 2f-g) . Surprisingly, the frequency of CFC, which normally comprise a large proportion of the CD34 þ population, decreased over the same time period. Thus, TEX cells exhibit a discordant differentiation program such that CD34 þ cells accumulate without a concomitant increase in clonogenic potential. Overall, these results indicate that in this experiment, extended culture of TLS-ERG cells resulted in the acquisition of additional changes that have conferred unlimited growth potential and resulted in the establishment of a human hematopoietic cell line originating from primary cells.
TEX cells retain multilineage differentiation capacity
To determine the differentiation capacity of TEX cells, we varied their cytokine environment. As in other TLS-ERG experiments, TEX cells were originally established in the presence of SCF and IL-3. Withdrawal of both cytokines resulted in rapid cell death, indicating that these cells are growth factor-dependent. However, TEX cells were able to grow in cultures supplemented with either SCF or IL-3 alone, although not as robustly. Analysis of cell surface antigens revealed that changes in the growth factor environment induced changes in the phenotype of TEX cells. IL-3 alone induced the rapid appearance of CD61 þ cells, whereas growth in SCF alone resulted in loss of CD61 þ cells (Figure 3a) . Growth in either cytokine alone resulted in a significant decrease in the proportion of CD34 þ cells (Figure 3b ), indicating that both signals are required for maintenance of this phenotype.
Analysis of morphology and cytochemistry revealed that TEX cells cultured with SCF and IL-3 appeared as undifferentiated blasts lacking myeloperoxidase (MPO) activity, with some exhibiting nonspecific esterase (NSE) activity (Figure 3c-e) . MPO and NSE activity are normally associated with myelocytic and monocytic lineages, respectively. Growth in IL-3 alone led to the appearance of granulated cells that were MPO negative, and an increase in the proportion of cells with high NSE activity (Figure 3f-h) . In contrast, SCF alone induced high MPO activity in the majority of cells with concomitant loss of NSE activity, despite retention of an immature phenotype by morphology (Figure 3i-k ). These findings demonstrate that different cytokines can induce rapid and distinct differentiation responses in TEX cells. However, these responses are aberrant, as evidenced by the discordance between morphologic appearance and presence of MPO/NSE activity. Thus, this experimentally derived cell line originating in primary human hematopoietic cells differs from most leukemic cell lines established from patient samples, in that it retains extensive ability to differentiate in response to physiologic cytokine regulators. This system establishes a foundation to explore responsiveness to a broad array of stimulators, providing a valuable model to study lineage commitment pathways in human cells.
TEX cells are functionally heterogeneous and exhibit a hierarchical organization
The phenotypic heterogeneity of TEX cells and their capacity for multilineage differentiation suggest that these cells are organized as a hierarchy maintained by primitive precursors. We performed limiting dilution analysis to assess whether TEX cells are functionally heterogeneous, and calculated the frequency of cells capable of sustaining proliferation in culture as one in 120 TEX cells (95% confidence limits one in 70 to one in 210) (Figure 4a) . Thus, only a minority of cells is able to sustain the clone in vitro.
To assess whether TEX cells also possess the ability to proliferate in an in vivo setting, we transplanted cells intravenously (i.v.) into sublethally irradiated NOD/SCID mice at doses of 10 to 50 Â 10 6 cells per mouse. Flow cytometric analysis of bone marrow aspirates performed 3-5 weeks posttransplantation revealed the presence of human CD45 þ cells in 20 of 22 mice, with engraftment ranging from 0.2 to 20% (Figure 4b ). Sustained engraftment for up to 5 months at low levels was observed in only a small fraction of mice (Table 1) . We have recently demonstrated that direct IF delivery of HSC can reveal stem cell properties in cells that do not engraft by i.v. methods. 31 IF injection of 1.5-2.5 Â 10 6 TEX cells into NOD/ SCID mice resulted in engraftment in 11 of 17 mice assessed after 3-5 weeks (Figure 4b ). Human cells were detected both in the injected femur and in the bone marrow from the other leg bones in all but one engrafted mouse, demonstrating that TEX graft-initiating cells are capable of mobilizing in vivo. cells. Overall, these results demonstrate that TEX cells are functionally heterogeneous, and exhibit a hierarchical organization similar to that seen in AML. 1 
TEX cells result from secondary events acquired during culture of TLS-ERG-transduced cells
The atypical behavior of TEX cells in vitro compared to other TLS-ERG cells suggested that additional genetic alterations had occurred in the former. Retroviral integration site analysis showed a monoclonal band in TEX cells, indicating the outgrowth of a single TLS-ERG-transduced clone (Figure 5a ). The TLS-ERG insertion site was cloned by linear amplificationmediated PCR and found to be in the 3 0 UTR of the forminbinding protein 17 (FBP17) gene on chromosome 9q34 (data not shown). Quantitative reverse transcription real-time PCR (qRT-PCR) showed no difference in FBP17 mRNA levels between TLS-ERG cells from another long-term culture and TEX cells (data not shown). Aliquots of TLS-ERG cells from this experiment that had Table 1 Engraftment of NOD/SCID mice transplanted intravenously with TEX cells been viably frozen after 14-133 days of culture were thawed and cultured under the same conditions (T14-T133). By integration site analysis, T14 cells remained polyclonal upon reculturing, with only a minor contribution by the TEX clone (Figure 5a ). In addition, T14, T47, and T69 cells exhibited growth kinetics typical of TLS-ERG cells, with proliferation peaking at approximately 3 months and subsequently declining (Figure 5b) . Together, these findings demonstrate that the observed growth kinetics of TEX cells were not due to inherent properties of the primary CB sample used in this experiment, or to insertional mutagenesis arising from retroviral integration.
In contrast to T14-69 cultures, T133 cells proliferated at the same rate as the continuously cultured TEX cells, and had the same single TLS-ERG integration site (Figure 5a-b) , suggesting that additional genetic changes conferring a proliferative advantage occurred between 69 and 133 days of the original culture, exactly within the time period when accelerated growth was observed in the bulk population (Figure 2a) . As a first step in identifying and characterizing secondary genetic events contributing to the transformation of TEX cells, we performed spectral karyotyping. After 213 days in culture, trisomy of chromosomes 10 and 19 was detected in 11 of 12 cells analyzed (Figure 5c ). T14 cells were karyotypically normal, whereas cells with trisomy 10 and 19 were detected in T133 cells (data not shown). Therefore, these genetic changes were acquired prior to or coincident with the clonal outgrowth of TEX cells, and likely conferred a growth advantage to the cells in which they arose.
TEX cells express Bmi-1
The polycomb group gene Bmi-1 is required for self-renewal of both normal and leukemic HSC in mice, 35, 36 leading us to hypothesize that Bmi-1 may be playing a role in the increased proliferation of TEX cells. Interestingly, the human Bmi-1 gene is located on chromosome 10. 37 qRT-PCR analysis showed that TEX cells after 508 days of culture expressed Bmi-1 RNA at levels 3.3-fold higher than observed in whole CB cells (Figure 6a) . Analysis of Bmi-1 expression over the course of the culture revealed an initially low level in TEX cells, which gradually increased for at least 508 days (Figure 6b) . Thus, trisomy 10, already present in all cells by 213 days of culture, does not solely account for the increase in Bmi-1 expression. In normal HSC, Bmi-1 is downregulated with differentiation. 35, 36 Significantly, we found that Bmi-1 protein levels are reduced in TEX cells that have undergone differentiation in response to IL-3 alone (Figure 6c ). These data indicate that a key component of the self-renewal machinery is present and developmentally regulated in TEX cells.
Telomerase plays a role in full transformation of TLS-ERG cells
Given the greatly increased proliferative output of TEX cells, we hypothesized that these cells must have acquired the ability to maintain telomere function. Telomerase activity in both TLS-ERG and Neo-transduced cells was low after 14-26 days of culture, demonstrating that TLS-ERG expression alone does not induce telomerase activity (Figure 6d) . However, by 140 days in culture, telomerase activity in TEX cells was high, at levels comparable to those seen in HeLa cells. T14 and T47 cells did not exhibit increased telomerase activity, indicating that the secondary event(s) resulting in elevated telomerase activity occurred after more than 47 days of culture.
The acquisition of, and selection for, elevated telomere activity in TEX cells are consistent with the demonstrated requirement for a telomere maintenance mechanism during cancer development. 38 Increased levels of telomerase have been observed in more than 70% of cases of AML. 39 We therefore introduced hTERT as a second engineered hit in a subset of our TLS-ERG cultures. Following 3-11 weeks of culture in myeloid promoting conditions, TLS-ERG cells were transduced with a lentiviral vector expressing hTERT or control GFP. In most cases, the TLS-ERG cells expressing hTERT or GFP grew with similar kinetics and morphology as cells expressing TLS-ERG alone (data not shown). However, in one of six experiments, cells expressing TLS-ERG and hTERT exhibited prolonged growth, and have now expanded more than 218 PD over 30 months (Figure 7a ). We consider these cells, termed T2a, to be immortalized. Unlike TEX cells, T2a cells did not exhibit an increase in growth rate for more than 1 year of culture and remained heterogeneous with myelomonocytic features (Figures 7a and b) . After 15 months, the growth rate of the culture plateaued for several weeks, following which the cells began to proliferate more rapidly, and subsequently acquired a uniform blast-like appearance (Figure 7c) . Spectral karyotyping at this time showed trisomy 8 and t(1;14)(q10;q10), which were not detected at 128 days of culture. Interestingly, cells that were viably frozen after 413 days of culture and subsequently thawed and regrown (T413) were also immortalized (Figure 7d ), but did not exhibit the same growth acceleration as continuously cultured T2a cells. Additionally, although these cells also had trisomy 8, they acquired a different translocation [t (1;22)(q10;q10) ]. These findings demonstrate that clonal evolution occurred differently in these two subcultures, and support the utility of this experimental model of preleukemic proliferation for identification and characterization of spontaneous events that occur during leukemic progression.
Discussion
Here we establish an experimental system of human leukemic development that provides direct evidence for the step-wise accumulation of transforming events. In this model, the leukemogenic program is initiated through disruption of the self-renewal, proliferation, and differentiation of primitive primary human hematopoietic cells by the TLS-ERG oncogene. This first event creates a preleukemic state in which additional leukemogenic alterations can accumulate. Using this approach, we established a novel human leukemic cell line (TEX) that exhibits the hierarchical organization of normal hematopoiesis and AML. The occurrence and selection for AML-associated secondary changes during evolution of both TEX and T2a demonstrates the power of this system to identify and characterize the sequential transforming events that lie at the heart of the human leukemogenic process.
Although solid tumor models have been established in other tissues, 4 this is the first system modeling cancer development in primary human blood cells. This and other studies have shown that the introduction of a single genetic element into normal human hematopoietic cells does not generate a full leukemic phenotype, 11, 15, 16, 22, 40 suggesting a requirement for multiple cooperating events. The generation of the TEX and T2a cell lines now provides direct evidence for the principle that leukemic transformation occurs through step-wise acquisition of multiple changes by normal human hematopoietic cells.
Our results provide insight into the cellular processes that need to be disrupted to initiate the leukemogenic program. TLS-ERG, a chimeric transcription factor, alters the differentiation, proliferation, and self-renewal of primitive hematopoietic cells 22 and, as we show here, can initiate leukemogenesis. Previously, we found that expression of TLS-ERG in committed progenitors never resulted in leukemic transformation. In this work, we used improved protocols enabling more efficient retroviral transduction of primitive stem cells, 24 allowing much longer in vitro growth and consequently greater expansion of target cells susceptible to acquisition of secondary events. Even in this context, however, transformation occurred infrequently. An essential element of tumorigenesis is the acquisition of unlimited replicative potential through maintenance of telomere function, and telomerase activity is elevated in the majority of AML cases. 39 A high level of telomerase activity was detected in TEX cells following acceleration of growth, indicating that increased telomerase activity may contribute, directly or indirectly, to minimal telomere maintenance and the increased proliferative potential of TEX cells. Our findings are consistent with the notion that telomerase activity is required for unlimited replicative potential of LSC. The addition of hTERT as a second hit in TLS-ERG cells led to establishment of a second transformed line. Nevertheless, the infrequency of transformation even with two engineered hits points to a requirement for further genetic alterations in order to achieve full transformation. Together, our studies imply that human leukemogenesis requires the expression of appropriate oncogenes within a cellular context that allows propagation of the initiating events.
The acquisition of secondary genetic changes (trisomy 10 and 19) in TEX cells coincided with their accelerated growth and phenotypic alteration. These changes were not detected in previously frozen samples of cells from the same culture that were thawed and regrown, and therefore were not intrinsic to the primary CB sample. Genetic alterations are retained if they confer a selective advantage, 41 thus the persistence of these karyotypic abnormalities in TEX cells suggests that they are not culture artefacts, but are relevant to the leukemogenic program in these cells. In support of this, trisomy 10 and 19 have both been documented as the sole chromosomal abnormality in numerous cases of AML. [42] [43] [44] [45] In fact, trisomy 19 in hematologic malignancy is observed most often in myelodysplasia and AML, and trisomy 10 is specifically associated with myeloblastic subtypes of AML. Further analysis of TEX cells will enable identification of the critical genes on these chromosomes that contribute to the leukemogenic process.
Interestingly, TEX cells carrying trisomy 10 and 19 accrued further genetic changes. The rapid emergence of CD34 þ cells after approximately 8 months in culture indicates that a proliferative advantage was acquired by a subpopulation of cells after trisomy 10 and 19 was already established in the bulk, mainly CD34
À , cell population. Spectral karyotyping after 22 months in culture demonstrated a new t(3,15)(q26-qter;qter) translocation in nine of 10 cells (data not shown). The 3q26 breakpoint is reported almost exclusively in myeloid leukemia or myelodysplasia in the Cancer Genome Anatomy Project (CGAP) database (cgap.nci.nih.gov). Furthermore, the karyotypic abnormalities identified in T2a cells are also associated with AML. A high proportion (60%) of trisomy 8 cases in the CGAP database are leukemia, the majority of which (41600) are AML. Interestingly, although the translocations acquired by continuously cultured T2a cells and the T413 subclone differ, both contain the 1q10 breakpoint. This breakpoint is present in 40 cases of AML in the CGAP database, but to date no causative genes have been identified in this region. Overall, these findings demonstrate the utility of this system for studying clonal evolution in leukemia, and for assessing the biological consequences of acquired transforming events.
A key characteristic of cancer stem cells is their capacity to self-renew. Bmi-1 has been identified as a critical regulator of self-renewal in normal and leukemic murine HSC, and is expressed predominantly by the primitive fractions of both normal and leukemic human hematopoietic cells. 35, 36, 46 We found that Bmi-1 RNA levels gradually increased in TEX cells over the duration of culture, such that levels after 16 months were more than three-fold higher than those found in normal CB cells. This persistent increase suggests either continual selection for cells expressing high Bmi-1 levels, or the occurrence of genetic or epigenetic changes leading to increased expression over time. Furthermore, the downregulation of Bmi-1 upon differentiation indicates that TEX cells retain the ability to regulate aspects of the self-renewal machinery, similar to what has been found in LSC. Collectively, these data indicate that Bmi-1 is contributing to the leukemogenic program in TEX cells. Interestingly, it is difficult to obtain primary murine (Guy Sauvageau, University of Montreal, personal communication) or human (Eric R Lechman and JED, unpublished data) hematopoietic cells that tolerate ectopically driven Bmi-1 overexpression. Thus, the finding of increased Bmi-1 expression in TEX cells suggests that during the leukemogenic process, compensating alterations must occur concomitantly.
Despite the occurrence of multiple transforming events affecting cell growth and differentiation, TEX cells exhibit a hierarchical organization and are capable of responding to physiologic cues. Thus, similar to what is seen in AML, the genetic changes acquired by TEX cells led to an aberrant developmental program that nonetheless retains elements of the normal hematopoietic hierarchy. TEX cells are functionally heterogeneous, with only rare cells capable of sustaining proliferation in vitro or in vivo following transplantation into NOD/SCID mice. The inability of TEX cells to sustain high levels of leukemic engraftment is in accordance with our observations that some AML samples engraft only transiently in this xenotransplant model, perhaps due to an inability of the murine microenvironment to support LSC long term (unpublished data). TEX cells also retain the capacity for myelomonocytic differentiation in response to physiologic cytokine regulators, although the observed maturation responses are aberrant, again reminiscent of the abnormal differentiation program specified in AML cells. 47, 48 The promiscuous expression of lymphoid and erythroid lineage-associated markers on some TEX cells suggests that this cell line may have evolved due to transformation of a 'primed' transcriptionally active multipotent stem cell prior to lineage commitment, 49 consistent with a model of AML in which the leukemogenic program is initiated and advanced in stem cells rather than committed progenitors. 1, 13, 14 However, because the initial transforming event used in our study (TLS-ERG) confers increased self-renewal capacity to myeloid progenitors, it is also possible that TEX cells originated in a transformed committed progenitor that was subsequently able to persist and acquire additional genetic changes. Nevertheless, the similarities between our TEX cell line and AML support the validity of using this in vitro approach to model human leukemogenesis.
Clearly, further analysis is required in order to fully define the molecular processes involved in converting normal human blood stem/progenitor cells into leukemic cells. We have demonstrated that TLS-ERG expression in primitive human hematopoietic cells leads to extended proliferation in vitro, resulting in the expansion of a target population and providing an environment for the occurrence and subsequent identification of secondary genetic changes relevant to human leukemogenesis. This system is well suited to the application of an insertional mutagenesis approach to identify these changes. As well, this system enables investigation of the role of candidate oncogenes in leukemic progression through the experimental introduction of additional genetic elements into TLS-ERGexpressing cells. Our findings demonstrate the power of this experimental system to give insight into the key elements of the human leukemogenic process.
